As this study has shown, anti-TK1-sdAb-IgG1 antibodies are capable of targeting mTK1 on cancer cells and elicit an ADCC response by human MNCs against TK1 high-level expressing cancer cells building on previous findings. Here, TK1 is linked to cancer.